• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Optimization of renin-angiotensin-aldosterone inhibitor therapies for evidence-based indications: A call to action from the cardio-kidney community.

作者信息

Pecoits-Filho Roberto, Wong Michelle M Y, Moorthy Monica, Banerjee Debasish, Behera Suman, Calice-Silva Viviane, Chothia Mogamat-Yazied, Colbert Gates B, Gulati Martha, Herzog Charles A, Jouhra Fadi, Lerma Edgar V, Malik Charu, Patel Kershaw V, Rakisheva Amina, Rosano Giuseppe M C, Satish Priyanka, Wu Henry H L, Wang Angela Yee-Moon

机构信息

Arbor Research Collaborative for Health, Ann Arbor, MI, USA.

Pontificia Universidade Catolica do Parana, Curitiba, Brazil.

出版信息

Am J Prev Cardiol. 2025 Jun 9;23:100663. doi: 10.1016/j.ajpc.2024.100663. eCollection 2025 Sep.

DOI:
10.1016/j.ajpc.2024.100663
PMID:40687934
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12275180/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21a2/12275180/2f917e175d5d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21a2/12275180/2f917e175d5d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21a2/12275180/2f917e175d5d/gr1.jpg

相似文献

1
Optimization of renin-angiotensin-aldosterone inhibitor therapies for evidence-based indications: A call to action from the cardio-kidney community.基于循证指征优化肾素-血管紧张素-醛固酮抑制剂治疗：来自心肾领域的行动呼吁。
Am J Prev Cardiol. 2025 Jun 9;23:100663. doi: 10.1016/j.ajpc.2024.100663. eCollection 2025 Sep.
2
Optimization of Renin-Angiotensin-Aldosterone Inhibitor Therapies for Evidence-Based Indications: a Call to Action From the Cardio-Kidney Community.肾素-血管紧张素-醛固酮抑制剂疗法针对循证指征的优化：来自心肾领域的行动呼吁。
Kidney Int Rep. 2025 Jun 9;10(7):2081-2087. doi: 10.1016/j.ekir.2025.03.036. eCollection 2025 Jul.
3
Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂和醛固酮拮抗剂联合肾素-血管紧张素系统拮抗剂对 2 型糖尿病合并慢性肾脏病患者主要肾脏不良结局的影响：系统评价和网络荟萃分析。
Diabetes Obes Metab. 2022 Nov;24(11):2159-2168. doi: 10.1111/dom.14801. Epub 2022 Jul 15.
4
Renin-Angiotensin-Aldosterone System Inhibitor Dosing After Initiation of Outpatient Sodium Zirconium Cyclosilicate Therapy: The GALVANIZE RAASi Real-World Evidence Study.门诊开始使用环硅酸锆钠治疗后肾素-血管紧张素-醛固酮系统抑制剂的剂量：GALVANIZE RAASi真实世界证据研究
Adv Ther. 2025 Jun 18. doi: 10.1007/s12325-025-03254-z.
5
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.用于射血分数保留的慢性心力衰竭的β受体阻滞剂和肾素-血管紧张素-醛固酮系统抑制剂。
Cochrane Database Syst Rev. 2018 Jun 28;6(6):CD012721. doi: 10.1002/14651858.CD012721.pub2.
6
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.醛固酮合酶抑制剂维卡司他（BI 690517）改善慢性肾脏病心肾结局的潜力：EASi-KIDNEY试验的理论依据
Nephrol Dial Transplant. 2025 May 30;40(6):1175-1186. doi: 10.1093/ndt/gfae263.
7
Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.直接肾素抑制的肾和心脏保护作用：系统文献综述。
J Hypertens. 2009 Dec;27(12):2321-31. doi: 10.1097/HJH.0b013e3283310f92.
8
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂在患有早期（1 至 3 期）非糖尿病慢性肾脏病的成人中的应用。
Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD007751. doi: 10.1002/14651858.CD007751.pub3.
9
Optimization of renin-angiotensin-aldosterone inhibitor therapies for evidence-based indications: a call to action from the cardio-kidney community.基于循证指征优化肾素-血管紧张素-醛固酮抑制剂治疗：来自心肾领域的行动呼吁。
ESC Heart Fail. 2025 Aug;12(4):2597-2604. doi: 10.1002/ehf2.15262. Epub 2025 Jun 9.
10
Blood pressure lowering efficacy of renin inhibitors for primary hypertension.肾素抑制剂对原发性高血压的降压疗效。
Cochrane Database Syst Rev. 2008 Oct 8(4):CD007066. doi: 10.1002/14651858.CD007066.pub2.

本文引用的文献

1
Managing Hyperkalemia in the Modern Era: A Case-Based Approach.现代高钾血症的管理：基于病例的方法。
Kidney Int Rep. 2023 Apr 24;8(7):1290-1300. doi: 10.1016/j.ekir.2023.04.016. eCollection 2023 Jul.
2
Prescription Pattern of Cation Exchange Resins and Their Efficacy in Treating Chronic Hyperkalemia Among Patients With Chronic Kidney Diseases: Findings From a Population-Based Analysis in British Columbia, Canada.阳离子交换树脂的处方模式及其在治疗慢性肾脏病患者慢性高钾血症中的疗效：来自加拿大不列颠哥伦比亚省一项基于人群分析的结果
Can J Kidney Health Dis. 2022 Nov 15;9:20543581221137177. doi: 10.1177/20543581221137177. eCollection 2022.
3
Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease.
肾素-血管紧张素系统抑制在晚期慢性肾脏病中的应用。
N Engl J Med. 2022 Dec 1;387(22):2021-2032. doi: 10.1056/NEJMoa2210639. Epub 2022 Nov 3.
4
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.KDIGO 2022慢性肾脏病糖尿病管理临床实践指南
Kidney Int. 2022 Nov;102(5S):S1-S127. doi: 10.1016/j.kint.2022.06.008.
5
Submaximal Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dosing Among Persons With Proteinuria.蛋白尿患者的次最大剂量血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂剂量。
Mayo Clin Proc. 2022 Nov;97(11):2099-2106. doi: 10.1016/j.mayocp.2022.07.010. Epub 2022 Oct 7.
6
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.用于射血分数降低的心力衰竭伴高钾血症管理的帕替络尔：DIAMOND 试验。
Eur Heart J. 2022 Nov 1;43(41):4362-4373. doi: 10.1093/eurheartj/ehac401.
7
Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice: A Cluster Randomized Trial.电子提醒改善门诊心力衰竭治疗：一项集群随机试验。
J Am Coll Cardiol. 2022 Jun 7;79(22):2203-2213. doi: 10.1016/j.jacc.2022.03.338. Epub 2022 Apr 3.
8
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1.
9
Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology.欧洲心脏病学会心力衰竭协会关于心力衰竭指南指导下药物治疗的肾脏效应：一份共识文件
Eur J Heart Fail. 2022 Apr;24(4):603-619. doi: 10.1002/ejhf.2471. Epub 2022 Mar 27.
10
Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.高钾血症相关的肾素-血管紧张素-醛固酮系统抑制剂停药与 CKD 临床结局的相关性：一项基于人群的队列研究。
Am J Kidney Dis. 2022 Aug;80(2):164-173.e1. doi: 10.1053/j.ajkd.2022.01.002. Epub 2022 Jan 25.